Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Guangzhou LBP Medicine Science & Technology Co (SHSE:688393) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Guangzhou LBP Medicine Science & Technology Co's EV-to-EBIT for today is
Guangzhou LBP Medicine Science & Technology Co's current Enterprise Value is ¥1,254.3 Mil.
Guangzhou LBP Medicine Science & Technology Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-43.5 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Guangzhou LBP Medicine Science & Technology Co's EV-to-EBITDA for today is:
Guangzhou LBP Medicine Science & Technology Co's current Enterprise Value is ¥1,254.3 Mil.
Guangzhou LBP Medicine Science & Technology Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-43.5 Mil.
Guangzhou LBP Medicine Science & Technology Co's current Enterprise Value is ¥1,254.3 Mil.
Guangzhou LBP Medicine Science & Technology Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥351.5 Mil.
Guangzhou LBP Medicine Science & Technology Co's current Enterprise Value is ¥1,254.3 Mil.
Guangzhou LBP Medicine Science & Technology Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥17.3 Mil.
Guangzhou LBP Medicine Science & Technology Co's current Enterprise Value is ¥1,254.3 Mil.
Guangzhou LBP Medicine Science & Technology Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-6.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou LBP Medicine Science & Technology Co Enterprise Value Related Terms
Guangzhou LBP Medicine Science & Technology Co Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou LBP Medicine Science & Technology Co Enterprise Value Chart
Guangzhou LBP Medicine Science & Technology Co Annual Data
SHSE:688393 vs ISRG, BDX, MDLN: Enterprise Value Comparison
For the Medical Instruments & Supplies subindustry, Guangzhou LBP Medicine Science & Technology Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guangzhou LBP Medicine Science & Technology Co Enterprise Value vs Medical Devices & Instruments Industry
Guangzhou LBP Medicine Science & Technology Co Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of ¥1,254.3 Mil mean?
Guangzhou LBP Medicine Science & Technology Co (SHSE:688393) has a Enterprise Value of ¥1,254.3 Mil as of Jul. 29, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Guangzhou LBP Medicine Science & Technology Co and its competitors.
Is Guangzhou LBP Medicine Science & Technology Co's Enterprise Value too high?
Guangzhou LBP Medicine Science & Technology Co's current Enterprise Value is ¥1,254.3 Mil. Overall, Guangzhou LBP Medicine Science & Technology Co has a GF Score™ of 62/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guangzhou LBP Medicine Science & Technology Co's Enterprise Value compare to ISRG and BDX?
Guangzhou LBP Medicine Science & Technology Co's Enterprise Value of ¥1,254.3 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Devices & Instruments company?
A good Enterprise Value depends on the Medical Devices & Instruments industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Guangzhou LBP Medicine Science & Technology Co and its competitors. Guangzhou LBP Medicine Science & Technology Co's current Enterprise Value is ¥1,254.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou LBP Medicine Science & Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Guangzhou LBP Medicine Science & Technology Co (SHSE:688393) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥25.52, compared to a current price of ¥17.17 — trading 32.7% below its estimated fair value. The current Enterprise Value is ¥1,254.3 Mil. Guangzhou LBP Medicine Science & Technology Co's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Guangzhou LBP Medicine Science & Technology Co (SHSE:688393), the current Enterprise Value is ¥1,254.3 Mil as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guangzhou LBP Medicine Science & Technology Co (SHSE:688393) Overvalued in 2026?
Based on GuruFocus' analysis, Guangzhou LBP Medicine Science & Technology Co stock appears to be undervalued.
The current stock price of ¥17.17 is trading 32.7% below its estimated GF Value™ of ¥25.52.
GuruFocus considers Guangzhou LBP Medicine Science & Technology Co to be Significantly Undervalued.
Key valuation signals for SHSE:688393:
Enterprise Value: ¥1,254.3 Mil
GF Value™: ¥25.52 vs. price of ¥17.17 (32.7% below fair value)
No single metric tells the full story. See the SHSE:688393 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guangzhou LBP Medicine Science & Technology Co Business Description
Guangzhou LBP Medicine Science & Technology Co Ltd is engaged in production and sales of in vitro diagnostic reagents and instruments. The company's products include Fluorescence in situ hybridization (FISH) series; Immunohistochemistry (IHC) series; Liquid - based cytology (LBP) series; PCR series; and medical laboratory.
62GF Score
Get the complete analysis for SHSE:688393
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688393 has been successfully added to your 
